Drugs

, Volume 45, Issue 2, pp 212–222 | Cite as

Prevention and Management of Gout

  • Vicki L. Star
  • Marc C. Hochberg
Practical Therapeutics

Summary

Gout is a common disease with a worldwide distribution. The major risk factor for the development of gout is sustained asymptomatic hyperuricaemia. Although pharmacological therapy of asymptomatic hyperuricaemia is not recommended, primary prevention of gout can be achieved through lifestyle changes including weight loss, restricting protein and calorie intake, limiting alcohol consumption, avoiding the use of diuretics in the treatment of hypertension, and avoiding occupational exposure to lead.

The arthritis of gout can be readily managed with the use of nonsteroidal anti-inflammatory drugs (NSAIDs); systemic steroids or corticotrophin (adrenocorticotrophic hormone; ACTH) should be used in patients with contraindications to NSAIDs, or who are intolerant of them. Because of potential toxicity, colchicine should not be used to treat acute gout, but should be used in low dosage (0.6 to 1.2 mg/day) for prophylaxis of recurrent attacks of gout.

The other cornerstone of prevention of recurrent gouty attacks is control of hyperuricaemia, which can be effectively accomplished with antihyperuricaemic therapy. The choice of agents, either uricosuric drugs or xanthine oxidase inhibitors, is based on the level of urinary uric acid excretion, renal function, age of patient, history of renal calculi and presence of tophi. Treatment and prevention of gout are exceedingly effective and patients can usually be managed by their primary care physician.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham study. Journal of Clinical Epidemiology 41: 237–242, 1988PubMedCrossRefGoogle Scholar
  2. Abramson SB. Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs. Current Opinion in Rheumatology 4: 295–300, 1992PubMedCrossRefGoogle Scholar
  3. Ali M, McDonald WD. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. Journal of Laboratory and Clinical Medicine 89: 868–875, 1977PubMedGoogle Scholar
  4. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of gout. Arthritis and Rheumatism 31: 803–805, 1988PubMedCrossRefGoogle Scholar
  5. Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. New England Journal of Medicine 300: 1459–1468, 1979PubMedCrossRefGoogle Scholar
  6. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. American Journal of Medicine 82: 421–426, 1987PubMedCrossRefGoogle Scholar
  7. Dawson DA, Adams PF. Current estimates from the National Health Interview Survey, United States, 1986. Vital and Health Statistics. Series 10, No. 164. DHHS Pub. No. (PHS) 87-1592. Public Health Service. Washington, U.S. Government Printing Office, Oct, 1987Google Scholar
  8. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Seminars in Arthritis and Rheumatism 19: 329–336, 1990PubMedCrossRefGoogle Scholar
  9. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. American Journal of Medicine 42: 27–37, 1967PubMedCrossRefGoogle Scholar
  10. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. American Journal of Medicine 76: 47–56, 1984PubMedCrossRefGoogle Scholar
  11. Hochberg MC. Opportunities for the primary and secondary prevention of gout. Mediguide Inflammatory Diseases 10: 1–5, 1991Google Scholar
  12. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, et al. Colchicine myopathy and neuropathy. New England Journal of Medicine 316: 1562–1568, 1987PubMedCrossRefGoogle Scholar
  13. Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Annals of Internal Medicine 88: 666–670, 1978PubMedGoogle Scholar
  14. Malawista SE. The action of colchicine in acute gouty arthritis. Arthritis and Rheumatism 18: 835–846, 1975PubMedCrossRefGoogle Scholar
  15. Masternard A, Giudicelli CP. Ten years experience with benz-bromarone in the management of gout and hyperuricemia. South African Medical Journal 59: 701–706, 1981Google Scholar
  16. Moreland LW, Ball GV. Colchicine and gout. Arthritis and Rheumatism 34: 782–786, 1991PubMedCrossRefGoogle Scholar
  17. Nicholls A, Scott JT. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 2: 1223–1224, 1972PubMedCrossRefGoogle Scholar
  18. Richter BS. A case-control study of lead exposure and other risk factors for gouty arthritis. PhD Thesis, The Johns Hopkins University, Baltimore, 1987Google Scholar
  19. Roberts WM, Liang MH, Stern SH. Colchicine in acute gout. Journal of the American Medical Association 257: 1920–1921, 1987PubMedCrossRefGoogle Scholar
  20. Roubenoff R, Klag MJ, Mead LA, Liang K-Y, Seidler AJ, et al. Incidence and risk factors for gout in white men. Journal of the American Medical Association 266: 3004–3007, 1991PubMedCrossRefGoogle Scholar
  21. Silman AJ, Hochberg MC. Epidemiology of the Rheumatic Diseases. Oxford University Press, Oxford, 1993Google Scholar
  22. Simkin PA. Management of gout. Annals of Internal Medicine 90: 812–816, 1979PubMedGoogle Scholar
  23. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis and Rheumatism 29: 82–87, 1986PubMedCrossRefGoogle Scholar
  24. Sterling LP. The clinical management of gout. American Pharmacy NS31: 368–374, 1991Google Scholar
  25. Talbott J, Yu TF. Gout and Uric Acid Metabolism, pp. (1–25), Stratton Intercontinental Medical Book Corp., New York, 1976Google Scholar
  26. Wallace SL, Bernstein D, Diamond H. Diagnostic value of the colchicine therapeutic trial. Journal of the American Medical Association 199: 525–528, 1967PubMedCrossRefGoogle Scholar
  27. Wallace SL, Robinson H, Masi AT, Decker JL, McCarthy DJ, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism 20: 895–900, 1977PubMedCrossRefGoogle Scholar
  28. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine — guidelines for use. Journal of Rheumatology 15: 495–499, 1988aPubMedGoogle Scholar
  29. Wallace SL, Singer JZ. Therapy in gout. Rheumatic Diseases Clinics of North America 14: 441–457, 1988bPubMedGoogle Scholar
  30. Wallace SL, Singer JZ, Duncan DJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. Journal of Rheumatology 18: 264–269, 1991PubMedGoogle Scholar
  31. Weiner IM. Inhibitors of tubular transport of organic compounds. In Gilman et al. (Eds) Goodman and Gilman’s textbook of pharmacology, 8th ed., pp. 743–748, Pergamon Press, London, 1990Google Scholar
  32. Wolfe F. Gout and hyperuricemia. American Family Physician 43: 2131–2150, 1991Google Scholar
  33. Yu TF, Gutman AB. Efficiency of colchicine prophylaxis in gout. Annals of Internal Medicine 55: 179–192, 1961PubMedGoogle Scholar
  34. Yu TF. The efficacy of colchicine prophylaxis in articular gout: a reappraisal after 20 years. Seminars in Arthritis and Rheumatism 12: 256–264, 1982PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Vicki L. Star
    • 1
  • Marc C. Hochberg
    • 1
    • 2
  1. 1.Division of Rheumatology and Clinical Immunology, Department of MedicineUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Department of Epidemiology and Preventive MedicineUniversity of Maryland School of MedicineBaltimoreUSA
  3. 3.Department of MedicineUniversity of Maryland School of MedicineBaltimoreMarylandUSA

Personalised recommendations